| |
|
|
| |
| |
Notes |
|
2009
R’million |
|
Restated
2008
R’million |
|
| CONTINUING OPERATIONS |
|
|
|
|
|
|
| Revenue |
24 |
|
8 450,3 |
|
4 682,5 |
|
| Cost of sales |
|
|
(4 564,1) |
|
(2 511,2) |
|
| Gross profit |
|
|
3 886,2 |
|
2171,3 |
|
| Other operating income |
|
|
4,1 |
|
89,1 |
|
| Selling and distribution expenses |
|
|
(997,7) |
|
(665,3) |
|
| Administrative expenses |
|
|
(588,6) |
|
(272,3) |
|
| Other operating expenses |
|
|
(121,0) |
|
(126,5) |
|
| Operating profit |
25 |
|
2 183,0 |
|
1 196,3 |
|
| Investment income |
28 |
|
224,2 |
|
263,4 |
|
| Financing costs |
29 |
|
(699,2) |
|
(280,7) |
|
| |
|
|
1 708,0 |
|
1 179,0 |
|
| Share of after-tax net losses of associates |
|
|
(3,3) |
|
(1,1) |
|
| Profit before tax |
|
|
1 704,7 |
|
1 177,9 |
|
| Tax |
30 |
|
(362,0) |
|
(333,1) |
|
| Profit after tax from continuing operations |
|
|
1 342,7 |
|
844,8 |
|
| DISCONTINUED OPERATIONS |
|
|
|
|
|
|
| Profit for the year from discontinued operations |
33 |
|
10,9 |
|
19,7 |
|
| Profit for the year |
|
|
1 353,6 |
|
864,5 |
|
| OTHER COMPREHENSIVE INCOME |
|
|
|
|
|
|
| Amounts recognised in equity due to hedge accounting of acquisitions |
|
|
— |
|
87,6 |
|
| Amounts recognised in equity due to hedge accounting of interest rate swaps |
|
|
(126,5) |
|
— |
|
| Cash flow hedges realised |
|
|
6,5 |
|
0,1 |
|
| Currency translation differences |
|
|
(399,9) |
|
117,3 |
|
| Acquisition of subsidiary |
|
|
4,8 |
|
52,5 |
|
| Disposal of 51% of Co-pharma Ltd |
|
|
— |
|
10,9 |
|
| Total comprehensive income |
|
|
838,5 |
|
1 132,9 |
|
| Profit for the year attributable to |
|
|
|
|
|
|
| Equity holders of the parent |
|
|
1 340,4 |
|
862,9 |
|
| Minority interests |
|
|
13,2 |
|
1,6 |
|
| |
|
|
1 353,6 |
|
864,5 |
|
| Total comprehensive income attributable to |
|
|
|
|
|
|
| Equity holders of the parent |
|
|
824,1 |
|
1 077,2 |
|
| Minority interests |
|
|
14,4 |
|
55,7 |
|
| |
|
|
838,5 |
|
1 132,9 |
|
| Earnings per share |
31 |
|
|
|
|
|
| Basic earnings per share (cents) |
|
|
|
|
|
|
| From continuing operations |
|
|
371,5 |
|
239,7 |
|
| From discontinued operations |
|
|
3,1 |
|
5,6 |
|
| |
|
|
374,6 |
|
245,3 |
|
| Diluted earnings per share (cents) |
|
|
|
|
|
|
| From continuing operations |
|
|
360,0 |
|
234,8 |
|
| From discontinued operations |
|
|
2,9 |
|
5,3 |
|
| |
|
|
362,9 |
|
240,1 |
|
|
| |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Headline earnings per share |
31 |
|
|
|
|
|
| |
Headline earnings per share (cents) |
|
|
|
|
|
|
| |
From continuing operations |
|
|
379,5 |
|
|
225,7 |
| |
From discontinued operations |
|
|
9,9 |
|
|
5,6 |
| |
|
|
|
389,4 |
|
|
231,3 |
| |
Headline earnings per share – diluted (cents) |
|
|
|
|
|
|
| |
From continuing operations |
|
|
367,5 |
|
|
221,7 |
| |
From discontinued operations |
|
|
9,2 |
|
|
5,3 |
| |
|
|
|
376,7 |
|
|
227,0 |
|
|
|
|
|
|
|
|
|
| |
|
|
|
| |
|
|
|
